Editorial
Copyright ©2010 Baishideng. All rights reserved.
World J Hepatol. Feb 27, 2010; 2(2): 55-57
Published online Feb 27, 2010. doi: 10.4254/wjh.v2.i2.55
Can proteomics lead to the discovery of real biomarkers for HCC?
Yasuhiro Kuramitsu
Yasuhiro Kuramitsu, Yamaguchi University Graduate School of Medicine, Department of Biochemistry and Functional Proteomics, 1-1-1 Minami-kogushi, Ube, Yamaguchi 755-8505, Japan
Author contributions: Kuramitsu Y solely contributed to this work.
Correspondence to: Dr. Yasuhiro Kuramitsu, MD, PhD, Yamaguchi University Graduate School of Medicine, Department of Biochemistry and Functional Proteomics 1-1-1 Minami-kogushi, Ube, Yamaguchi 755-8505, Japan. climates@yamaguchi-u.ac.jp
Telephone: +81-836-222213 Fax: +81-836-222212
Received: September 4, 2009
Revised: January 9, 2010
Accepted: January 16, 2010
Published online: February 27, 2010
Abstract

The development of proteomics technologies has lead to a great deal of effort being focused on the identification of biomarkers for cancers. Although many papers have reported candidate biomarkers for hepatocellular carcinomas (HCCs) in particular, so far none of these candidate biomarkers have been used either for diagnosis or therapy intreating patients. The question remains: Can proteomics identify real biomarkers for HCCs?

Keywords: Hepatocellular carcinoma, Proteomics, Mass spectrometry, Two-dimensional polyacrylamide gel electrophoresis, Biomarker